fenoldopam has been researched along with Disease Exacerbation in 2 studies
Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fenoldopam is a dopamine receptor alpha1-specific agonist that increases renal blood flow in patients with kidney failure." | 2.71 | Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial. ( Cotsonis, G; Finkel, KW; Murray, PT; Samuels, J; Shaw, AD; Tumlin, JA, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tumlin, JA | 1 |
| Finkel, KW | 1 |
| Murray, PT | 1 |
| Samuels, J | 1 |
| Cotsonis, G | 1 |
| Shaw, AD | 1 |
| Mehran, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Combination Fenoldopam Mesylate and Intravenous MESNA (2-mercaptoethane Sulphonate)in Early Acute Kidney Injury (AKD): A Randomized, Double-Blind Placebo Controlled Clinical Trial[NCT00286403] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2008-08-31 | Withdrawn (stopped due to The study was terminated due to logistics at a local hospital.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fenoldopam and Disease Exacerbation
| Article | Year |
|---|---|
Contrast-induced nephropathy remains a serious complication of PCI.
Topics: Acetylcysteine; Angioplasty, Balloon, Coronary; Contrast Media; Disease Progression; Fenoldopam; Hum | 2007 |
1 trial available for fenoldopam and Disease Exacerbation
| Article | Year |
|---|---|
Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial.
Topics: Creatinine; Diabetes Complications; Disease Progression; Dopamine Agonists; Double-Blind Method; Ear | 2005 |